CN1051548C - 杂双环衍生物、含有它们的药物组合物及其制备方法与用途 - Google Patents

杂双环衍生物、含有它们的药物组合物及其制备方法与用途 Download PDF

Info

Publication number
CN1051548C
CN1051548C CN95194959A CN95194959A CN1051548C CN 1051548 C CN1051548 C CN 1051548C CN 95194959 A CN95194959 A CN 95194959A CN 95194959 A CN95194959 A CN 95194959A CN 1051548 C CN1051548 C CN 1051548C
Authority
CN
China
Prior art keywords
phenyl
alkyl
amino
contain
carboxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN95194959A
Other languages
English (en)
Chinese (zh)
Other versions
CN1157617A (zh
Inventor
岛崎宪彦
泽田昭彦
渡边真也
逸见惠次
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of CN1157617A publication Critical patent/CN1157617A/zh
Application granted granted Critical
Publication of CN1051548C publication Critical patent/CN1051548C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CN95194959A 1994-07-11 1995-07-10 杂双环衍生物、含有它们的药物组合物及其制备方法与用途 Expired - Fee Related CN1051548C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9413975A GB9413975D0 (en) 1994-07-11 1994-07-11 New heterobicyclic derivatives
GB9413975.5 1994-07-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN99111945A Division CN1250776A (zh) 1994-07-11 1999-07-29 杂双环衍生物

Publications (2)

Publication Number Publication Date
CN1157617A CN1157617A (zh) 1997-08-20
CN1051548C true CN1051548C (zh) 2000-04-19

Family

ID=10758154

Family Applications (2)

Application Number Title Priority Date Filing Date
CN95194959A Expired - Fee Related CN1051548C (zh) 1994-07-11 1995-07-10 杂双环衍生物、含有它们的药物组合物及其制备方法与用途
CN99111945A Pending CN1250776A (zh) 1994-07-11 1999-07-29 杂双环衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN99111945A Pending CN1250776A (zh) 1994-07-11 1999-07-29 杂双环衍生物

Country Status (19)

Country Link
US (2) US6426345B1 (ru)
EP (2) EP0770079B1 (ru)
JP (1) JP3206003B2 (ru)
KR (1) KR100394761B1 (ru)
CN (2) CN1051548C (ru)
AT (1) ATE232531T1 (ru)
AU (1) AU698133B2 (ru)
CA (1) CA2194872A1 (ru)
DE (1) DE69529614T2 (ru)
DK (1) DK0770079T3 (ru)
ES (1) ES2187561T3 (ru)
GB (1) GB9413975D0 (ru)
HK (1) HK1004483A1 (ru)
HU (1) HUT77353A (ru)
MX (1) MX9700308A (ru)
PT (1) PT770079E (ru)
RU (2) RU2170737C2 (ru)
TW (1) TW383307B (ru)
WO (1) WO1996001825A1 (ru)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
US7772432B2 (en) 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
GB9816837D0 (en) * 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US6517834B1 (en) 1995-08-04 2003-02-11 Geron Corporation Purified telomerase
US6545133B1 (en) 1995-08-04 2003-04-08 Geron Corporation Methods for purifying telomerase
GB9526558D0 (en) * 1995-12-27 1996-02-28 Fujisawa Pharmaceutical Co Heterobicyclic derivatives
SE9603283D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
DE19710609A1 (de) 1997-03-14 1998-09-17 Bayer Ag Substituierte Aminosalicylsäureamide
AR017200A1 (es) 1997-12-23 2001-08-22 Astrazeneca Ab Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
SE9800835D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
CN1328555A (zh) * 1998-09-29 2001-12-26 藤泽药品工业株式会社 吡啶并吡嗪化合物的新的盐及其结晶
JP2002539187A (ja) * 1999-03-17 2002-11-19 アストラゼネカ アクチボラグ アミド誘導体
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
US6346625B1 (en) 1999-06-23 2002-02-12 Astrazeneca Ab Protein kinase inhibitors
DE60043318D1 (de) 1999-08-21 2010-01-14 Nycomed Gmbh Synergistische kombination von pumafentrine und salmeterol
ATE362926T1 (de) 2000-01-20 2007-06-15 Eisai R&D Man Co Ltd Stickstoffhaltige cyclische verbindungen und sie enthaltende pharmazeutische zubereitungen
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
DK1257550T3 (da) * 2000-02-04 2006-03-27 Portola Pharm Inc Blodplade-ADP-receptor-inhibitor
GB0006133D0 (en) * 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
EP1712239A3 (en) 2000-05-12 2007-08-22 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
JP4160295B2 (ja) * 2000-12-08 2008-10-01 武田薬品工業株式会社 ３−ピリジル基を有する置換チアゾール誘導体、その製造法および用途
JP5025057B2 (ja) * 2001-05-10 2012-09-12 株式会社半導体エネルギー研究所 半導体装置の作製方法
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
KR100490970B1 (ko) * 2002-03-22 2005-05-24 씨제이 주식회사 신규 피리도[2,3-ｄ]피리미딘 카르보알데히드 옥심계ＰＤＥ Ⅳ 효소 저해 화합물 및 이의 제조방법
PT1525200E (pt) * 2002-08-02 2008-01-10 Ab Science 2-(3-aminoaril)amino-4-aril-tiazóis para o tratamento de doenças
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
CA2497192A1 (en) * 2002-09-16 2004-03-25 Alcon Manufacturing, Ltd. Use of pde iv inhibitors to treat angiogenesis
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004209456A1 (en) 2003-02-03 2004-08-19 Janssen Pharmaceutica N.V. Quinoline-derived amide modulators of vanilloid VR1 receptor
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
PT1636228E (pt) * 2003-05-23 2009-02-02 Aeterna Zentaris Gmbh Novas piridopirazinas e sua utilização como moduladores de cinases
DE10323345A1 (de) * 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
ES2332184T3 (es) 2004-03-22 2010-01-28 ELI LILLY & COMPANY Derivados de piridilo y su uso como antagonistas del receptor mglu5.
WO2006126081A2 (en) * 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
EP1746096A1 (en) * 2005-07-15 2007-01-24 4Sc Ag 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
KR101423483B1 (ko) 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법
RU2515944C9 (ru) * 2005-11-11 2014-07-20 Этерна Центарис ГмбХ ПРОИЗВОДНЫЕ ПИРИДОПИРАЗИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ФИЗИОЛОГИЧЕСКИХ И/ИЛИ ПАТОФИЗИОЛОГИЧЕСКИХ СОСТОЯНИЙ ПОСРЕДСТВОМ ИНГИБИРОВАНИЯ ФЕРМЕНТОВ ERK, ERK1, ERK2, PI3K, PI3Kальфа, PI3Kбета, PI3Kгамма, PI3Kдельта, PI3K-С2альфа, PI3K-С2бета, PI3K-Vps34р (ВАРИАНТЫ)
US20080280891A1 (en) * 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008008059A1 (en) * 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
HUE033849T2 (en) * 2008-03-05 2018-01-29 Merck Patent Gmbh Pyridopyrazinone derivative for insulin secretagogues, methods for their preparation and their use in the treatment of diabetes
FR2930552B1 (fr) * 2008-04-24 2012-10-12 Centre Nat Rech Scient N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9580471B2 (en) 2011-03-01 2017-02-28 Synergy Pharmaceuticals, Inc. Process of preparing guanylate cyclase C agonists
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
CN104739820B (zh) * 2014-09-30 2017-02-15 三峡大学 一种小分子抑制剂及在抑制鸟氨酸脱羧酶上的应用
US20170314007A1 (en) * 2014-09-30 2017-11-02 China Three Gorges University Medicament design pocket of ornithine decarboxylase and application of medicament design pocket
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008864A1 (en) * 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA794209B (en) * 1978-08-15 1980-07-30 Fisons Ltd Pharmaceutically active heterocyclic compounds
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
GB9526558D0 (en) 1995-12-27 1996-02-28 Fujisawa Pharmaceutical Co Heterobicyclic derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008864A1 (en) * 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
HU9700068D0 (en) 1997-02-28
DE69529614D1 (de) 2003-03-20
AU2899295A (en) 1996-02-09
RU2170737C2 (ru) 2001-07-20
GB9413975D0 (en) 1994-08-31
CN1250776A (zh) 2000-04-19
MX9700308A (es) 1997-05-31
WO1996001825A1 (en) 1996-01-25
RU2001107897A (ru) 2003-01-20
DK0770079T3 (da) 2003-06-10
KR100394761B1 (ko) 2003-11-20
TW383307B (en) 2000-03-01
PT770079E (pt) 2003-06-30
DE69529614T2 (de) 2003-07-03
ATE232531T1 (de) 2003-02-15
AU698133B2 (en) 1998-10-22
US6426345B1 (en) 2002-07-30
US20020107251A1 (en) 2002-08-08
HUT77353A (hu) 1998-03-30
EP0920867A1 (en) 1999-06-09
ES2187561T3 (es) 2003-06-16
CN1157617A (zh) 1997-08-20
JPH10502630A (ja) 1998-03-10
EP0770079A1 (en) 1997-05-02
JP3206003B2 (ja) 2001-09-04
HK1004483A1 (en) 1998-11-27
US6727245B2 (en) 2004-04-27
CA2194872A1 (en) 1996-01-25
EP0770079B1 (en) 2003-02-12

Similar Documents

Publication Publication Date Title
CN1051548C (zh) 杂双环衍生物、含有它们的药物组合物及其制备方法与用途
CN1058710C (zh) 苯甲酰胺衍生物及其制法、用途和含其的药物组合物
CN1043344C (zh) 杂环化合物,制备方法,药物组合物和用途
CN1130351C (zh) 1,5－苯并二氮杂䓬衍生物
CN1048484C (zh) 含苯并杂环化合物的药物组合物的制备方法
CN1230431C (zh) 用作类胰蛋白酶抑制剂的芳基甲胺衍生物
CN1035670C (zh) 一种制备苯并杂环化合物或其盐的方法
CN1078889C (zh) 非肽类速激肽受体拮抗剂
CN1041929C (zh) 新的杂环衍生物及其制备方法和用途,和含该衍生物的药物组合物
CN1046724C (zh) 吡唑并吡啶化合物、含有它们的药物组合物、及其制法与用途
CN1255401C (zh) 芳基－哌嗪衍生物、及其制备和作为速激肽拮抗剂的应用
CN1031376A (zh) 吡唑并吡啶化合物及其制备方法
CN1107476A (zh) 杂环化合物及其制备和应用
CN1192729A (zh) 苯甲酰胺衍生物和它们作为后叶加压素拮抗剂的应用
CN1022187C (zh) 三环化合物的制备方法
CN1278793A (zh) 磺酰基衍生物
CN1070173C (zh) 用作药物的苯甲酰基胍衍生物
CN1867553A (zh) 作为cdk 和/或vegf 抑制剂的氨基亚砜取代的嘧啶化合物、其制备方法以及作为药物的用途
CN1678586A (zh) 取代的喹啉ccr5受体拮抗剂
CN1209803A (zh) 微粒体甘油三酯转移蛋白的构象限制性芳族抑制剂及方法
CN1168667A (zh) 用作缓激肽拮抗剂的吡啶并嘧啶酮，喹啉和稠合的n-杂环化合物
CN1313280A (zh) 苯并杂环衍生物
CN1209125A (zh) 作为速激肽拮抗剂的哌嗪类衍生物
CN1639132A (zh) N－吡嗪基－苯磺酰胺及其在治疗趋化因子介导疾病中的用途
CN1064042C (zh) 苯并吖庚因衍生物的中间体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee